NCT01377480View on ClinicalTrials.gov

A Study of the Use of Oral Posaconazole (POS) in the Treatment of Asymptomatic Chronic Chagas Disease (P05267)

PHASE2CompletedINTERVENTIONAL

Enrollment

120

Participants

Timeline

Start Date

July 6, 2011

Primary Completion Date

July 22, 2014

Study Completion Date

January 12, 2015

Conditions

Chagas Disease

Interventions

DRUG

Posaconazole

POS 40 mg/mL oral suspension

DRUG

Placebo for posaconazole

Placebo oral suspension

DRUG

Benznidazole

BNZ 100 mg oral tablet

All Listed Sponsors

lead

Merck Sharp & Dohme LLC

INDUSTRY

NCT01377480 - A Study of the Use of Oral Posaconazole (POS) in the Treatment of Asymptomatic Chronic Chagas Disease (P05267) | Biotech Hunter | Biotech Hunter